Haemonetics - HAE Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HAE shares.
View HAE analyst ratings or view top-rated stocks.

6 analysts have issued twelve-month price targets for Haemonetics' stock. Their HAE share price forecasts range from $74.00 to $90.00. On average, they predict the company's stock price to reach $82.80 in the next year. This suggests a possible upside of 14.9% from the stock's current price.
View analysts price targets for HAE or view top-rated stocks among Wall Street analysts.

Haemonetics' stock was trading at $53.04 at the beginning of the year. Since then, HAE shares have increased by 35.8% and is now trading at $72.05.
View the best growth stocks for 2022 here.

Haemonetics saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 1,720,000 shares, a decline of 7.5% from the August 31st total of 1,860,000 shares. Based on an average daily trading volume, of 428,400 shares, the days-to-cover ratio is presently 4.0 days. Approximately 3.4% of the company's stock are sold short.
View Haemonetics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our HAE earnings forecast.

Haemonetics Co. (NYSE:HAE) posted its quarterly earnings results on Wednesday, August, 10th. The medical instruments supplier reported $0.58 EPS for the quarter, topping the consensus estimate of $0.51 by $0.07. The medical instruments supplier had revenue of $261.50 million for the quarter, compared to the consensus estimate of $249 million. Haemonetics had a net margin of 6.60% and a trailing twelve-month return on equity of 18.62%. The company's quarterly revenue was up 14.4% compared to the same quarter last year. During the same period last year, the business posted $0.50 EPS.

Haemonetics updated its FY 2023 earnings guidance on Friday, September, 9th. The company provided earnings per share (EPS) guidance of $2.60-$2.90 for the period, compared to the consensus earnings per share estimate of $2.73. The company issued revenue guidance of $1.07 billion-$1.10 billion, compared to the consensus revenue estimate of $1.06 billion.

48 employees have rated Haemonetics Chief Executive Officer Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among the company's employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), APA (APA), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE).

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Haemonetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include LGT Capital Partners LTD. (1.93%), Royce & Associates LP (1.64%), Northern Trust Corp (1.29%), Boston Trust Walden Corp (1.19%), River Road Asset Management LLC (0.91%) and Point72 Asset Management L.P. (0.80%). Insiders that own company stock include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Laurie A Miller, Mark W Kroll, Mark W Kroll, Michelle L Basil, Michelle L Basil, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh, Stewart W Strong and William P Mr Burke.
View institutional ownership trends.

Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HAE stock can currently be purchased for approximately $72.05.

Haemonetics (NYSE:HAE) has a market capitalization of $3.70 billion and generates $993.20 million in revenue each year. The medical instruments supplier earns $43.38 million in net income (profit) each year or $1.31 on an earnings per share basis.

The company employs 2,821 workers across the globe.

Haemonetics' mailing address is 125 Summer Street, Boston MA, 02110. The official website for the company is www.haemonetics.com. The medical instruments supplier can be reached via phone at (781) 848-7100, via email at gerry.gould@haemonetics.com, or via fax at 781-848-5106.